ASCO GI 2023 | Molecular testing for cholangiocarcinoma

Shubham Pant, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, talks on the requirement for molecular testing with next-generation sequencing (NGS) for cholangiocarcinoma to enable treatment of patients with the associated targeted therapy, as well as to allocate patients to the appropriate clinical trial. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Gastrointestinal Cancers (GI) Symposium in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.